默沙东（MRK）今日盘中股价大幅上涨5%，表现显著强于大盘。
消息面上，公司近期发布的财报显示业绩超出市场预期，营收和每股收益均高于分析师预估，并且重申了2026年全年的盈利指引，稳健的财务基本面为股价提供了有力支撑。
与此同时，公司在研药物管线取得了一系列积极进展。其用于治疗晚期肺癌的在研疗法calderasib（与Keytruda联用）获得了美国食品药品监督管理局（FDA）的突破性疗法认定；另一关键资产sacituzumab tirumotecan在多种癌症类型中展现出前景；与Moderna合作开发的个体化癌症疫苗也公布了积极的长期随访数据。此外，其HIV新药多拉韦林伊拉曲韦片近日被中国国家药品监督管理局药品审评中心（CDE）拟纳入优先审评，公司还宣布与多家中国本土药企签署了肿瘤领域的合作协议，持续拓展研发布局。
这些积极的临床、监管及业务进展，叠加制药板块整体的回暖情绪，以及机构投资者的增持行为和分析师的乐观评级，共同推动了默沙东股价在今日交易时段内走强。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.